Specificity and Structure of a High Affinity Activin Receptor-like Kinase 1 (ALK1) Signaling Complex

被引:141
|
作者
Townson, Sharon A. [1 ]
Martinez-Hackert, Erik [1 ]
Greppi, Chloe [1 ]
Lowden, Patricia [1 ]
Sako, Dianne [1 ]
Liu, June [1 ]
Ucran, Jeffrey A. [1 ]
Liharska, Katia [1 ]
Underwood, Kathryn W. [1 ]
Seehra, Jasbir [1 ]
Kumar, Ravindra [1 ]
Grinberg, Asya V. [1 ]
机构
[1] Acceleron Pharma, Cambridge, MA 02139 USA
关键词
CRYSTAL-STRUCTURE; ACTIVATION; EXPRESSION; BMP9; ENDOTHELIUM; MECHANISM; DOMAIN; TOOL;
D O I
10.1074/jbc.M112.377960
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Activin receptor-like kinase 1 (ALK1), an endothelial cell-specific type I receptor of the TGF-beta superfamily, is an important regulator of normal blood vessel development as well as pathological tumor angiogenesis. As such, ALK1 is an important therapeutic target. Thus, several ALK1-directed agents are currently in clinical trials as anti-angiogenic cancer therapeutics. Given the biological and clinical importance of the ALK1 signaling pathway, we sought to elucidate the biophysical and structural basis underlying ALK1 signaling. The TGF-beta family ligands BMP9 and BMP10 as well as the three type II TGF-beta family receptors ActRIIA, ActRIIB, and BMPRII have been implicated in ALK1 signaling. Here, we provide a kinetic and thermodynamic analysis of BMP9 and BMP10 interactions with ALK1 and type II receptors. Our data show that BMP9 displays a significant discrimination in type II receptor binding, whereas BMP10 does not. We also report the crystal structure of a fully assembled ternary complex of BMP9 with the extracellular domains of ALK1 and ActRIIB. The structure reveals that the high specificity of ALK1 for BMP9/10 is determined by a novel orientation of ALK1 with respect to BMP9, which leads to a unique set of receptor-ligand interactions. In addition, the structure explains how BMP9 discriminates between low and high affinity type II receptors. Taken together, our findings provide structural and mechanistic insights into ALK1 signaling that could serve as a basis for novel anti-angiogenic therapies.
引用
收藏
页码:27313 / 27325
页数:13
相关论文
共 50 条
  • [21] Transcription Factor 7-Like 2 (TCF7L2) Regulates Activin Receptor-Like Kinase 1 (ALK1)/Smad1 Pathway for Development of Diabetic Nephropathy
    Araoka, Toshikazu
    Abe, Hideharu
    Tominaga, Tatsuya
    Mima, Akira
    Matsubara, Takeshi
    Murakami, Taichi
    Kishi, Seiji
    Nagai, Kojiro
    Doi, Toshio
    MOLECULES AND CELLS, 2010, 30 (03) : 209 - 218
  • [22] Activin receptor-like kinase 1 is implicated in the maturation phase of angiogenesis
    Lamouille, S
    Mallet, C
    Feige, JJ
    Bailly, S
    BLOOD, 2002, 100 (13) : 4495 - 4501
  • [23] Immunohistochemical Analysis of Activin Receptor-Like Kinase 1 (ACVRL1/ALK1) Expression in the Rat and Human Hippocampus: Decline in CA3 During Progression of Alzheimer's Disease
    Adams, Stephanie L.
    Benayoun, Laurent
    Tilton, Kathy
    Mellott, Tiffany J.
    Seshadri, Sudha
    Blusztajn, Jan Krzysztof
    Delalle, Ivana
    JOURNAL OF ALZHEIMERS DISEASE, 2018, 63 (04) : 1433 - 1443
  • [24] P7170, a novel inhibitor of mTORC1/mTORC2 and Activin receptor-like Kinase 1 (ALK1) inhibits the growth of non small cell lung cancer
    Venkatasubbaiah A Venkatesha
    Asavari Joshi
    Magesh Venkataraman
    Vinay Sonawane
    Dimple Bhatia
    Prashant Tannu
    Julie Bose
    Sarika Choudhari
    Ankita Srivastava
    Prashant Kumar Pandey
    Vaibhavi J Lad
    Ramachandra Sangana
    Tausif Ahmed
    Anagha Damre
    Vijaykumar Deore
    Bichismita Sahu
    Sanjay Kumar
    Somesh Sharma
    Veena R Agarwal
    Molecular Cancer, 13
  • [25] Activin Receptor-Like Kinase Receptors ALK5 and ALK1 Are Both Required for TGFβ-Induced Chondrogenic Differentiation of Human Bone Marrow-Derived Mesenchymal Stem Cells
    de Kroon, Laurie M. G.
    Narcisi, Roberto
    Davidson, Esmeralda N. Blaney
    Cleary, Mairead A.
    van Beuningen, Henk M.
    Koevoet, Wendy J. L. M.
    van Osch, Gerjo J. V. M.
    van der Kraan, Peter M.
    PLOS ONE, 2015, 10 (12):
  • [26] P7170, a novel inhibitor of mTORC1/mTORC2 and Activin receptor-like Kinase 1 (ALK1) inhibits the growth of non small cell lung cancer
    Venkatesha, Venkatasubbaiah A.
    Joshi, Asavari
    Venkataraman, Magesh
    Sonawane, Vinay
    Bhatia, Dimple
    Tannu, Prashant
    Bose, Julie
    Choudhari, Sarika
    Srivastava, Ankita
    Pandey, Prashant Kumar
    Lad, Vaibhavi J.
    Sangana, Ramachandra
    Ahmed, Tausif
    Damre, Anagha
    Deore, Vijaykumar
    Sahu, Bichismita
    Kumar, Sanjay
    Sharma, Somesh
    Agarwal, Veena R.
    MOLECULAR CANCER, 2014, 13
  • [27] Advances in the discovery of activin receptor-like kinase 5 (ALK5) inhibitors
    Mansour, Mai A.
    Hassan, Ghaneya S.
    Serya, Rabah A. T.
    Jaballah, Maiy Y.
    Abouzid, Khaled A. M.
    BIOORGANIC CHEMISTRY, 2024, 147
  • [28] MAPPING OF 2 HUMAN GENES ENCODING ACTIVIN RECEPTOR-LIKE KINASES (ALK1 AND ALK4) TO 12Q11-]Q14
    STENMAN, G
    TENDIJKE, P
    ROIJER, E
    MIYAZONO, K
    FRANZEN, P
    VANKESSEL, AG
    HELDIN, GH
    CYTOGENETICS AND CELL GENETICS, 1994, 67 (04): : 274 - 274
  • [29] Phase II evaluation of dalantercept, a soluble recombinant activin receptor-like kinase 1 (ALK1) receptor-fusion protein, for treatment of recurrent/persistent endometrial cancer: GOG-0229N.
    Makker, Vicky
    Filiaci, Virginia L.
    Chen, Lee-may
    Darus, Christopher
    Kendrick, James Erasmus
    Sutton, Gregory
    Moxley, Katherine
    Aghajanian, Carol
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [30] Activin receptor-like kinase 1 as a target for anti-angiogenesis therapy
    Hawinkels, Lukas J. A. C.
    de Vinuesa, Amaya Garcia
    ten Dijke, Peter
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2013, 22 (11) : 1371 - 1383